Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684166 | 0.86 | ALDH1A1 (0.41) | ACACBRAB9AALDH1A1HTTSLC6A2 | |
| SCHEMBL20282831 | 0.84 | ALDH1A1 (0.39) | ACACBRAB9AALDH1A1HTTNPY5R | |
| SCHEMBL680880 | 0.81 | GAA (0.44) | ACACBALDH1A1HTTSLC6A2SLC6A3 | |
| SCHEMBL681837 | 0.79 | ACACB (0.42) | ACACBALDH1A1HTTSLC6A2SLC6A3 | |
| SCHEMBL12168671 | 0.78 | PYGL (0.39) | ACACBRAB9AALDH1A1HTTSLC6A2 | |
| SCHEMBL681500 | 0.78 | SLC6A2 (0.46) | ACACBRAB9AALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL22622560 | 0.77 | AVPR1A (0.33) | AVPR1ASMN1; SMN2 | |
| SCHEMBL20892764 | 0.77 | ACACB (0.44) | ACACBRAB9AALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL680890 | 0.77 | ACACB (0.44) | ACACBRAB9AALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL17804037 | 0.77 | ALDH1A1 (0.40) | ACACBRAB9AALDH1A1HTTSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | ACACB 3006/4885RAB9A 1697/4885ALDH1A1 2098/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | ACACB 3204/4885RAB9A 1810/4885ALDH1A1 1715/4885 |
| US-20140349997-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | ACACB 3204/4885RAB9A 1810/4885ALDH1A1 1715/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | ACACB 3204/4885RAB9A 1810/4885ALDH1A1 1715/4885 |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | ACACB 3204/4885RAB9A 1810/4885ALDH1A1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.